收费全文 | 11304篇 |
免费 | 777篇 |
国内免费 | 82篇 |
耳鼻咽喉 | 94篇 |
儿科学 | 294篇 |
妇产科学 | 240篇 |
基础医学 | 1938篇 |
口腔科学 | 173篇 |
临床医学 | 1078篇 |
内科学 | 2853篇 |
皮肤病学 | 225篇 |
神经病学 | 1019篇 |
特种医学 | 218篇 |
外科学 | 891篇 |
综合类 | 49篇 |
一般理论 | 1篇 |
预防医学 | 990篇 |
眼科学 | 166篇 |
药学 | 957篇 |
中国医学 | 38篇 |
肿瘤学 | 939篇 |
2024年 | 9篇 |
2023年 | 132篇 |
2022年 | 242篇 |
2021年 | 531篇 |
2020年 | 257篇 |
2019年 | 367篇 |
2018年 | 426篇 |
2017年 | 304篇 |
2016年 | 296篇 |
2015年 | 392篇 |
2014年 | 448篇 |
2013年 | 644篇 |
2012年 | 904篇 |
2011年 | 932篇 |
2010年 | 495篇 |
2009年 | 448篇 |
2008年 | 765篇 |
2007年 | 798篇 |
2006年 | 722篇 |
2005年 | 674篇 |
2004年 | 570篇 |
2003年 | 554篇 |
2002年 | 499篇 |
2001年 | 33篇 |
2000年 | 40篇 |
1999年 | 59篇 |
1998年 | 95篇 |
1997年 | 62篇 |
1996年 | 48篇 |
1995年 | 35篇 |
1994年 | 15篇 |
1993年 | 21篇 |
1992年 | 15篇 |
1991年 | 12篇 |
1990年 | 9篇 |
1989年 | 11篇 |
1988年 | 11篇 |
1987年 | 16篇 |
1986年 | 12篇 |
1985年 | 21篇 |
1984年 | 15篇 |
1982年 | 9篇 |
1981年 | 26篇 |
1980年 | 14篇 |
1978年 | 14篇 |
1977年 | 16篇 |
1976年 | 9篇 |
1975年 | 9篇 |
1972年 | 8篇 |
1971年 | 9篇 |
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献Background
Pneumococcal diseases remain a major cause of morbidity and mortality worldwide. Updated data on drug-resistance from different populations may be important to recognize changes in disease patterns. This study assessed current levels of penicilin resistance among Streptococcus Pneumoniae causing pneumonia in Spanish middle age and older adults. 相似文献Methods: Thirty-six elective surgical patients were initially enrolled. Conditions approximating steady state were obtained for sevoflurane and target-controlled propofol infusions. Patients were sequentially evaluated for LOC (loud voice plus mild prodding) and immobility to surgical incision. The study was designed using the Dixon up-down method.
Results: The observed propofol effect target with 50% response plus sevoflurane (0.46% end-tidal concentration) was 1.2 [mu]g/ml (95% confidence interval, 1.1-1.3 [mu]g/ml). It was not significantly different from that predicted (1.5 [mu]g/ml; 95% confidence interval, 1.2-1.7 [mu]g/ml) by simple additivity. The effective plasma concentration of propofol that suppressed movement to skin incision in 50% of patients was 5.4 [mu]g/ml (95% confidence interval, 4.8-6.0 [mu]g/ml) plus sevoflurane (0.86%) and was not significantly different from that predicted by additivity (5.4 [mu]g/ml; 95% confidence interval, 4.8-5.9 [mu]g/ml). Both analyses had adequate power (90%) to detect a significant change (+/-19 to 25%) from predicted value. Repeated-measures analysis of variance identified a Bispectral Index value of 70 as the break point between those who responded at LOC or did not. 相似文献